	1
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO .: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO. (PE STUDIES ONLY):	
EP008011.033	

PASS INFORMATION

Title	Post-marketing study to assess serotype-specific effectiveness of Reassortant Rotavirus Vaccine, Live, Oral, Pentavalent (Vero Cell) (ROTATEQ [®]) in China
Protocol Version identifier	Version 6.0
Date of last version of protocol	12-May-2023
EU PAS Register No:	EUPAS36666
Active substance	G1: 2.2×10^6 infectious units ; G2: 2.8×10^6 infectious units ; G3: 2.2×10^6 infectious units ; G4: 2.0×10^6 infectious units ; P1A[8]: 2.3×10^6 infectious units
Medicinal product(s):	Reassortant Rotavirus Vaccine, Live, Oral, Pentavalent (Vero Cell)
Product reference:	V260
Procedure number:	Not Applicable
Marketing authorisation holder(s) (MAH)	Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc. 126 East Lincoln Ave., P.O. Box 2000, Rahway, New Jersey 07065 USA.
Joint PASS	No
Research question and objectives	The objective of this non-interventional study is to assess the serotype-specific effectiveness of ROTATEQ® after large scale use in China
Country(-ies) of study	China
Author	PPD Associate Principal Scientist, Biostatistical and Research Decision Sciences (BARDS) Epidemiology,
	Merck Sharp & Dohme LLC., PPD

	2
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024
Marketing authorisation holder(s) including MAH Contact Person	Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc. 126 East Lincoln Ave., P.O. Box 2000, Rahway, New Jersey 07065 USA.
Merck Final Repository (REDS) Date	14-OCT-2024
Date of Health Authority Approval of Protocol	

PRODUCT: V-260 REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033 PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0 CORE DRC APPROVAL DATE: 7-JUNE-2024 3

TABLE OF CONTENTS

PA	SS INI	FORMATION	1
TA	BLE (OF CONTENTS	3
LI	ST OF	TABLES	5
LI	ST OF	FIGURES	6
LI	ST OF	ABBREVIATIONS	7
1	RES	PONSIBLE PARTIES	8
2	ABS	TRACT	8
3	AME	ENDMENT UPDATES	13
4	MIL	ESTONES	25
5	RAT	IONALE AND BACKGROUND	25
6	RES	EARCH QUESTIONS AND OBJECTIVES	27
	6.1	Primary Objectives	27
7	RES	EARCH METHODS	28
	7.1	Study Design	28
	7.2	Setting	28
	7.3	Variables	29
	7.3	B.1 Exposure	29
	7.3	3.2 Outcomes	29
	7.3	3.3 Covariates	30
	7.4	Data Sources	30
	7.4	I.1 Study Procedures	31
	7.5	Study Size	35
	7.6	Data Management	37
	7.7	Programming Quality	38
	7.8	Data Analysis	39
	7.9	Quality Control	40
	7.10	Limitations of the Research Methods	40
	7.11	Other Aspects	41
8	PRO	TECTION OF HUMAN SUBJECTS	41
	8.1	Informed Consent	41
9	MAN	AGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE	
	REA	CTIONS	42
	9.1	Adverse Event and Product Quality Complaint Reporting	42
	9.1	.1 Investigator Responsibility	42
	9.1	.2 Study Report	44

	4
PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0	
CORE DRC APPROVAL DATE: 7-JUNE-2024	
late Reports	45
	45
)	45
AR): also referred to as Adverse Drug Reaction	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	45
ent (SAE)/Serious Adverse Reaction (SAR)	45
e Reaction (NSAR)	45
	45
mplaint (PQC)	46
	46
	46
Causality Assessment	
	47
Oversight	47
NG AND COMMUNICATING STUDY	
	47
	48
	52
uments	52
on for Pharmacovigilance (GQPPV), EU/UK	
	53
	54
13.1 Sponsor's Representative	
	55
	56
	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0 CORE DRC APPROVAL DATE: 7-JUNE-2024 ate Reports

	5
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO .: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY):	
EP008011.033	

LIST OF TABLES

Table 1	Serotype-specific efficacy and effectiveness of ROTATEQ® in clinical trials and post-marketing studies conducted out of China	26
Table 2	Total number of cases needed to provide 80% probability to observe a lower 95% confidence bound of VE greater than zero for the first primary objective and second primary objective	36
Table 3	Probability of observing a point estimate of VE for the first primary objective and second primary objective in final analysis and interim analysis	37
Table 4	AE and PQC Reporting Timeframes and Process for Investigators and Suppliers	44

	6
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024

LIST OF FIGURES

Figure 1	Flow chart for post-marketing study to assess serotype-specific effectiveness of ROTATEQ® against RVGE receiving treatments in hospitals and tested positive for at least one of the RV serotypes	
	G2/G3/G4	32
Figure 2	Procedures of eligible patients enrollment and data generation in the present study	33

	7
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO .: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY):	
EP008011.033	

LIST OF ABBREVIATIONS

95% CI	95% confidence interval
AE	Adverse Event
AGE	Acute gastroenteritis
CCI	
DSUR	Development Safety Update Report
ELISA	Enzyme Linked Immunosorbent Assay
EMA	European Medicines Agency
EMR	Electronical Medical Record
FDA	Food and Drug Administration
GPP	Good Pharmacoepidemiology Practice
IRB	Institutional Review Board
LLR	Lanzhou Lamb Rotavirus Vaccine
OR	Odds ratio
PBRER	Periodic Benefit Risk Evaluation Report
PCR	Polymerase Chain Reaction
PDC	Primary Data Collection
PQCs	Product Quality Complaints
PSUR	Periodic Safety Update Report
RV	Rotavirus
RVGE	Rotavirus acute gastroenteritis
SAP	Statistical Analysis Plan
SDC	Secondary Data Collection
SOP	Standard Operating Procedure
VE	Vaccine effectiveness
WHO	World Health Organization

	8
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO .: V260-077/V6.0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024

1 RESPONSIBLE PARTIES

Principal investigator	Jie Wu
Coordinating investigator for each country in which the study is to be performed	Not applicable
Sponsor contacts	PPD
Other contacts	Not applicable
Supplier/Collaborator	Hangzhou Tigermed Consulting Co.,Ltd
Investigators	Not applicable
Shared responsibilities	Not applicable

2 ABSTRACT

Title	Post-marketing study to assess serotype-specific effectiveness of the Reassortant Rotavirus Vaccine, Live, Oral, Pentavalent (Vero Cell) (ROTATEQ [®]) in China	
Protocol Number / Version	Version 6.0	
Date	7-June-2024	
Author	MSD R&D (China) Co., Ltd	

	9
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO. (PE STUDIES ONLY):	
EP008011.033	

Rationale & Background	In clinical trials and post-marketing studies abroad, ROTATEQ [®] demonstrated consistently high efficacy and effectiveness against severe rotavirus gastroenteritis (RVGE) of >90%. Serotype-specific efficacy and effectiveness against genotypes G2P[4], G3P[8] and G4P[8] was > 80% in those studies. However, in the China Phase 3 trial, serotype-specific efficacy was only demonstrated for RV serotypes G1 and G9, and not for G2, G3 and G4 because those serotypes were not circulating in the study region during the period when the study was performed. ROTATEQ [®] received marketing authorization in China in April 2018,		
Research Question(s) & Objective(s)Primary Objective(s)	 Primary objective To assess the effectiveness of ROTATEQ[®] in children treated in the hospital for RVGE due to at least one of the RV serotypes G2/G3/G4. To assess the effectiveness of ROTATEQ[®] in children treated in the hospital for RVGE due to at least one of the RV serotypes G1/G2/G3/G4/G9. 		
Study Design	Test-negative case-control design		
Study Population	Children age-eligible to be fully vaccinated with 3 doses of ROTATEQ [®] and receiving treatment for acute gastroenteritis (AGE) in hospitals.		
Variables	Exposure: Vaccination with ROTATEQ [®] . Outcome: RV positive AGE (serotype-specific) receiving treatments in hospitals.		

PRODUCT: V-260		PROTOCOL/AMENDMENT VERSION NO · V260-077/V6 0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033		CORE DRC APPROVAL DATE: 7-JUNE-2024
Data Sources	A h ider neg hosj abo con lab inte incl vac	ybrid data collection study to prospectively ntify serotype-specific RVGE cases and RV ative AGE controls receiving treatments in pitals and vaccination cards, providing information ut ROTATEQ [®] vaccination status of cases and trols. The primary data collection (PDC) includes testing results and information collected by rviews while secondary data collection (SDC) udes the data collection from EMR and cination records.
Study Size	Bas (ma esti: Ass AG foll G2/ rota hav 85 c exp seas acco hos of 6 be a of t a po obs	ed on current enrollment rate, approximately 7,393 aximum 7,600) age-eligible AGE cases are mated to be included by end of the fourth season. numing RVGE representing 33% of all cause of E in the peak season (October to April of the owing year), 4.5% of RVGE are due to serotypes (G3/G4, 97% of enrolled AGE cases with complete avirus vaccination information, and 20% of them ing been vaccinated with other rotavirus vaccines, cases of RVGE due to serotypes G2/G3/G4 are ected to be included in the final analysis after four sons. Assuming 25% ROTATEQ [®] coverage ording to the recommended schedule in selected pital catchment areas during the study period, a VE 60%, and 30 controls available by case, there will around 80% probability to observe a lower bound the 95% CI of VE >0%, 85% probability to observe point estimate of VE >45%, or 76% probability to erve a point estimate of VE >50%.
	For RV ⁴ case incl Ass case obse prol or 9 VE ² Fina seas RO ²	the second primary objective, assuming 50% of GE are due to serotypes G1/G2/G3/G4/G9, 946 es due to G1/G2/G3/G4/G9 are expected to be uded in the final analysis after four seasons. The sample of 60% and 3 controls available by e, the sample size provides >99% probability to erve a lower bound of 95% CI of VE >0%, >99% bability to observe a point estimate of VE >45%, 99% probability to observe a point estimate of >50%. al VE will be estimated based on data from four sons, among children eligible to be vaccinated with TATEO [®] .

	1
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024
	One interim analysis will be conducted by a third

party after the 3rd season. By then, it is expected that 5,200 AGE cases, 59 cases due to G2/G3/G4 and 665 cases due to G1/G2/G3/G4/G9 will be accumulated. For the first primary objective of VE against RVGE due to serotypes G2/G3/G4, there will be a probability of 65%, 81%, or 73% to observe a lower bound of the 95% CI of VE >0%, a point estimate of VE > 45%, or a point estimate of VE >50%, respectively. For the second primary objective of VE against RVGE due to serotypes G1/G2/G3/G4/G9, there will be a probability of >95% CI of VE >0%, so point estimate of VE against RVGE due to serotypes G1/G2/G3/G4/G9, there will be a probability of >95% is to observe a lower bound of the 95% CI of VE >0%, >99% probability to observe a point estimate of VE >45%, or 99% probability to observe a point estimate of VE >50%, respectively.
The interim analysis will be submitted to DMC for review. Based on pre-specified criteria in the DMC charter, the DMC might provide a recommendation to anticipate the end of enrollment in the study.

PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024
Data Analysis	VE will be calculated by one minus the odds ratios for ROTATEQ [®] receipts for rotavirus case subjects compared with test-negative controls.
	Adjusted VE will be estimated by multivariate logistic regression model, adjusting for potential confounders, and presented with 95% confidence interval.
	The following indicators will be computed (by selected hospitals and year if relevant) and described:
	• Number of AGE cases in children age-eligible to be vaccinated with ROTATEQ [®] ;
	• Number of RVGE cases in children age-eligible to be vaccinated with ROTATEQ [®] ;
	• Number of G1, G2, G3, G4, G9 AGE cases (by each serotype and in aggregate) in children age- eligible to be vaccinated with ROTATEQ [®] .
	Matched analyses (including Propensity Score Matching, PSM) will be done as sensitivity analysis. More details will be provided in the Statistical Analysis Plan.
Milestones	
Start of data collection:	Q4/2020
End of data collection:	Q2/2025
Interim report(s) of study results:	Q3/2023
Study progress report(s):	Q2/2022
Final report of study results:	Q1/2026

	13
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011 033	

3 AMENDMENT UPDATES

Amend ment or Update no	Date	Section of Study Protocol	Amendment or Update	Reason	CORE DRC Appro val Date	COR E DRC Versi on No
<1>	18- DEC- 2019	Template	Template was changed from secondary data collection to primary data collection.	Update to retain only the primary data collection	18- DEC- 2019	V1.0
<2>	18- DEC- 2019	ABSTR ACT: Start of data collectio n:	The wording referring to secondary data source study was removed.	Update to retain only the primary data collection	18- DEC- 2019	V1.0
<3>	18- DEC- 2019	ABSTR ACT: Final report of study results:	Changed from "March, 2022" to "Before applying licensure renewal"	Updated to reflect timeline	18- DEC- 2019	V1.0
<4>	18- DEC- 2019	7.2 Exclusio n criteria	Exclusion criteria specific for secondary data source study were removed;	Update to retain only the primary data collection	18- DEC- 2019	V1.0

PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024

Amend ment or Update no	Date	Section of Study Protocol	Amendment or Update	Reason	CORE DRC Appro val Date	COR E DRC Versi on No
<5>	18- DEC- 2019	7.4 Data sources	Secondary data sources. i.e., China CDC AGE surveillance network introduction and its feasibility assessment was removed. Information about the primary data collection were copied from previous section 7.10 to current section 7.4.	Update to retain only the primary data collection	18- DEC- 2019	V1.0
<6>	18- DEC- 2019	7.4.1 Study procedur es	The follow chart and the description were updated to reflect the primary data collection procedures	Updated flowchart to make it clear.	18- DEC- 2019	V1.0

PRODUCT: V-260
REVOPS ID NO: NIS00

REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033

PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0 CORE DRC APPROVAL DATE: 7-JUNE-2024

Amend ment or Update no	Date	Section of Study Protocol	Amendment or Update	Reason	CORE DRC Appro val Date	COR E DRC Versi on No
	18- DEC-	7.5 Study	Due to the fact that a primary data collection study would include children who have AGE symptoms whereas a secondary data collection study would directly include RV genotype data, the sample size needed some adjustments, the following assumptions were added to calculate the sample size of age- eligible AGE cases that need to be screened to demonstrate 60% VE with 80% statistical power using 1:3 ratio case control design: - RVGE representing 30% of all cause AGE in China - 90% of RVGE are due to G1/G2/G3/G4/G9 serotypes The sample size might be re-calculated once the hospitals are selected and the assumptions are better known (coverage,	Update to make it	18- DEC- 2019	V1.0
<7>	2019	size	etc.).	clear		

etc.).

	16
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO. (PE STUDIES ONLY):	
EP008011.033	

Amend ment or Update		Section of Study			CORE DRC Appro val Date	COR E DRC Versi on
no	Date	Protocol	Amendment or Update	Reason		No
<8>	18- DEC- 2019	7.6 Data Manage ment	Activities referring to the China CDC surveillance network were removed.	Update to retain only the primary data collection	18- DEC- 2019	V1.0
<9>	18- DEC- 2019	7.9 Limitatio ns of the research methods	Limitations for secondary data source study were removed.	Update to retain only the primary data collection	18- DEC- 2019	V1.0
<10>	18- DEC- 2019	9.1 Adverse events reporting	Procedures for secondary data collection were removed	Update to retain only the primary data collection	18- DEC- 2019	V1.0
<11>	May 26th, 2020	Section 6.1	Moved the "VE against G2/G3/G4" from secondary to the primary objective		July 23rd, 2020	V2.0
<12>	May 26th, 2020	Section 7.5	Recalculated the sample size per updated primary objective		July 23rd, 2020	V2.0
<13>	15- June- 2021	CRF V2.1	Added the father's and mother's education level		19- JULY- 2021	
<14>	15- June- 2021	CRF V2.1	Removed the vaccination information in the key consideration of enrollment	Address external experts' comment	19- JULY- 2021	

Confidential

	17
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO .: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO. (PE STUDIES ONLY):	
EP008011.033	

Amend					CORE DRC Appro	COR E DRC
ment or Undate		Section of Study			val Date	Versi
no	Date	Protocol	Amendment or Update	Reason		No
<15>	15- June- 2021	CRF V2.1	Removed Rotavirus detection and genotyping results	To combine the external lab data into EDC instead of entering	19- JULY- 2021	
<16>	Septem ber 23rd, 2021	Section 5	Updated epidemic season from October-March to October to April.	Extend the enrollment period according to recent epidemiolo gical data of RV.	Novem ber 10th, 2021	V3.0
<17>	Septem ber 23rd, 2021	Section 7.2	Revised "at least two" to "at least three" RV peak seasons.	Extend the study duration according to actual enrollment speed.	Novem ber 10th, 2021	V3.0
<18>	Septem ber 23rd, 2021	Section 7.4	Revised ~200 stool samples per hospital per year to ~100 stool samples per hospital per year.	Adjust the site selection criteria according to actual number of enrolled cases.	Novem ber 10th, 2021	V3.0

	18
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024

Amend ment or Update no	Date	Section of Study Protocol	Amendment or Update	Reason	CORE DRC Appro val Date	COR E DRC Versi on No
<19>	Septem ber 23rd, 2021	Section 7.4.1	Revised the flow.	Revised the flow to make it clear.	Novem ber 10th, 2021	V3.0
<20>	Septem ber 23rd, 2021	Section 9.1.2	Removed 'The Risk Management Sub-team (RMST) Lead /Clinical Safety Risk Manager (CSRM) Physician will be notified if any safety data are generated in the final study report or any interim report. The safety and conclusion sections of the final study report or interim report must be reviewed by the RMST Lead/CSRM Physician prior to finalization of the report. The review by the CSRM Physician must occur prior to any release of results to the public domain in the form of abstracts, posters, presentations or manuscripts. '	Removed the paragraph from template according to CORE DRC confirmati on.	Novem ber 10th, 2021	V3.0
	Septem ber 23rd.	Section	Added section of Data	CCI	Novem ber 10th.	V3.0
<21>	2021	9.5.1	monitoring committee.		2021	

	19
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024

Amend ment or Undate		Section of Study			CORE DRC Appro val Date	COR E DRC Versi
no	Date	Protocol	Amendment or Update	Reason		No
<22>	Septem ber 23rd, 2021	Through out protocol	Used the 12-Jul-2021 PASS PDC 12 template	Updated the template to use the template from July 2021	Novem ber 10th, 2021	V3.0
<23>	May 25th, 2022	Section 7.2	Added specifications regarding gastroenteritis onset and treatment length (consecutive calendar days)"	Added to make it clear	14- July- 2022	V4.0
<24>	May 25th, 2022	Section 7.4	Increase from 10 to 30 hospitals planned to participate in the study	Updated according to 2nd season	14- July- 2022	V4.0
<25>	May 25th, 2022	Section 7.4	Updated the case control ratio	Updated according to the available data of 1st and 2nd seasons	14- July- 2022	V4.0
<26>	May 25th, 2022	Section 7.5	Updated the sample size	Updated according the available data of 1st and 2nd seasons	14- July- 2022	V4.0

		20
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO .: V260-077/V6.0	
<u>REVOPS ID NO: NIS008322</u> EPIDEMIOLOGY NO.(PE STUDIES ONLY):	CORE DRC APPROVAL DATE: 7-JUNE-2024	
EP008011 033		

Amend ment or Update no	Date	Section of Study Protocol	Amendment or Update	Reason	CORE DRC Appro val Date	COR E DRC Versi on No
				CCI	14- July- 2022	V4.0
<27>	May 25th, 2022	Section 7.5	Added the sample size when considering the confounders			
	May		Added matched analyses (by age, gender and calendar time) as sensitivity analyses for		14- July- 2022	V4.0
<28>	25th, 2022	Section 7.7	the first and second primary objectives			

	2	21
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0	
<u>REVOPS ID NO: NIS008322</u> EPIDEMIOLOGY NO.(PE STUDIES ONLY):	CORE DRC APPROVAL DATE: 7-JUNE-2024	
EP008011 033		

Amend ment or Update no	Date	Section of Study Protocol	Amendment or Update	Reason	CORE DRC Appro val Date	COR E DRC Versi on No
~20>	May 25th,	Section	Updated the DMC	CCI	14- July- 2022	V4.0
<30>	Mar 23th, 2023	Section 1	Update Principal investigator information	Update Principal investigato r informatio n	28- April- 2023	V5.0
<31>	Mar 23th, 2023	Section 7.1	Updated the sample size case control ratio in study design	Updated according to the available data of 1- 3 rd seasons	28- April- 2023	V5.0
<32>	Mar 23th, 2023	Section 7.2	Updated study duration	Updated according to the available data of 1- 3 rd seasons	28- April- 2023	V5.0
<33>	Mar 23th, 2023	Section 7.4.1	Changed case:control ratio to 1:30 for the first primary objective; changed case:control ratio to 1:3 for the second primary objective	Updated according to the available data of 1- 3 rd seasons	28- April- 2023	V5.0

	22
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY):	
EP008011.033	

Amend ment or Update no	Date	Section of Study Protocol	Amendment or Update	Reason	CORE DRC Appro val Date	COR E DRC Versi on No
<34>	Mar 23th, 2023	Section 7.5	Changed vaccine coverage rate to 25%	Updated according to the available data of 1- 3 rd seasons	28- April- 2023	V5.0
<35>	Mar 23th, 2023	Section 7.5	Changed content of Table 2 (sample size calculation for a case control design for the first and second primary objective)	Updated according to the available data of 1- 3 rd seasons	28- April- 2023	V5.0
<36>	Mar 23th, 2023	Section 7.5	Removed Table 3 (sample size estimation considering confounders) and related wordings	To increase the statistical power, sample size was calculated without considerin g the confounder s	28- April- 2023	V5.0
<37>	Mar 23th, 2023	Section 7.5	Added Table 3 of Probability of observing a point estimate of VE for the first primary objective and second primary objective in final analysis and interim analysis	Added probability based on different scenarios	28- April- 2023	V5.0

	23
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY):	
EP008011.033	

Amend ment or Update	Dete	Section of Study	A more device 4 on The data	Decor	CORE DRC Appro val Date	COR E DRC Versi on
no	Date	Protocol	Amendment or Update	Reason	28	NO V5.0
<38>	Mar 23th, 2023	Section 7.7	Added interim analysis and DMC review	aligned to add an interim analysis and DMC review	28- April- 2023	V3.0
<39>	Mar 23th, 2023	Section 7.7	Added matched analyses (parents' education level) as sensitivity analyses for the first and second primary objectives	CCI	28- April- 2023	V5.0
<40>	Mar 23th, 2023	Section 7.9	Change case control ratio	Changed case control ratio to 1:30	28- April- 2023	V5.0
<41>	Mar 23th, 2023	Section 9.5.1	The composition and responsibility of DMC was updated, with one vaccinologist/virologist/p ediatrician and DMC will review the available data from the study including the interim analysis data.	To reflect the update of DMC role on interim analysis	28- April- 2023	V5.0
<42>	April 15 th , 2024	Whole	The study protocol template was changed from primary data collection to hybrid data collection	To reflect hybrid data collection including primary and secondary data collection	7-June- 2024	V6.0

PRODUCT: V-260
REVOPS ID NO: NIS008322
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033

PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0 CORE DRC APPROVAL DATE: 7-JUNE-2024 24

Amend					CORE DRC Appro	COR E DRC
ment or Update	Data	Section of Study Protocol	Amondmont or Undata	Donson	Date	Versi on No
<43>	April 15 th , 2024	Section 7.3.3	Added or edited covariates of Residence location, Symptom Onset Seasons, Birth season, Region of study hospital, Clinical setting, Parents education level	To add all covariates in the study	7-June- 2024	V6.0
<44>	April 15 th , 2024	Section 7.4	Added "The primary data collection (PDC) includes the lab testing results and information collected by interviews while secondary data collection (SDC) includes the data collection from EMR and vaccination records."	To define the scope of PDC and SDC	7-June- 2024	V6.0
<45>	April 15 th , 2024	Section 9	The study outcome include AGE, including RV positive and RV negative AGE. AGE cases should not be reported as SAE.	Study endpoints should not be reported as SAE in the study	7-June- 2024	V6.0
<46>	April 15 th , 2024	Section 7.8	Added sentence "Besides assessing the VE predefined in the study objectives, the data might be used for other research purposes."	To explore further analysis based on dataset if applicable	7-June- 2024	V6.0

PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024

4 MILESTONES

Milestone	Planned Date
<registration eu="" in="" pas="" register="" the=""></registration>	September 3 rd , 2020
Start of data collection	Q4/2020
End of data collection	Q2/2025
<study 1="" progress="" report=""></study>	Q2/2022
Interim report(s) of study results	Q3/2023
Final report of study results	Q1/2026

5 RATIONALE AND BACKGROUND

Rotavirus (RV) is the leading cause of severe diarrhea in infants and young children. RV infection was responsible for an estimated 128,500 deaths and 258 million episodes of diarrhea worldwide among children younger than 5 years of age in 2016.[1] In 2009, World Health Organization (WHO) recommended RV vaccination for all children worldwide, especially in countries with high number of diarrhea-associated deaths.[2] In China, RV caused over 40% of diarrhea hospitalizations and about 30% of diarrhea related outpatients visits in children aged < 5 years. Over 50% of RV-related hospitalizations in China occurred by age 1 year and about 90% occurred by age 2 years;[3] this indicates that a vaccination program with doses given early in infancy has the potential to prevent the majority of the burden of severe RV disease in China.[4] The peak seasonality of RV activity in China is typically from October to April of the following year, although this may vary regionally to include additional months.[5]

There are 3 RV vaccines currently approved for marketing in China: Lanzhou Lamb Rotavirus (LLR, Lanzhou Institute of Biological Products) vaccine, ROTATEQ [®] (Merck & Co., Inc., Kenilworth, NJ, USA), and trivalent Lanzhou Lamb Rotavirus (LLR3, Lanzhou Institute of Biological Products). [®]LLR vaccine has been in use in China since 2000,[6] and includes the genotype G10P[15].[7] It has been widely distributed in China with a coverage up to 20.3% in some regions.[8] To our knowledge, no clinical trials to estimate the efficacy of LLR have been published. Results from a few post-marketing effectiveness studies for LLR performed in China, using different study designs, are not consistent ranging from 35.0% to 77%.[7], [9], [10], [11], [12], [13] The serotype-specific effectiveness of LLR against G3 and G9 has been reported to be respectively 52.0% and 40.8%. No VE results against the serotypes G1, G2, and G4 have been published so far. LLR3 vaccine has been

PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024

launched on the Chinese market since April 2023, and includes the serotypes G2, G3 and G4.[14]

ROTATEQ[®] was approved for marketing in China on April 12th, 2018. ROTATEQ[®] is an oral, live pentavalent (G1, G2, G3, G4, and P1A[8]) human–bovine (WC3) reassortant rotavirus vaccine. The vaccine is indicated for the prevention of RV gastroenteritis in infants and children caused by the serotypes G1, G2, G3, G4, and G9.[15] ROTATEQ[®] has a restrictive age-indication with a first dose to be administered at age 6 to 12 weeks, subsequent doses with a 4- to 10- weeks interval and the third dose at no later than 32 weeks of age.[15]

The serotype-specific efficacy and effectiveness of ROTATEQ[®] has been widely assessed in clinical trials[16] and in several post-marketing studies worldwide.[17], [18], [19] ROTATEQ[®] demonstrated high overall and serotype-specific efficacy/effectiveness against both severe (hospitalized and/or Vesikari Score ≥ 11) RV gastroenteritis (RVGE) and RVGE of any severity. The results from these studies are summarized in Table 1. Statistically significant vaccine effectiveness (VE) results could only be obtained for serotypes that circulated in a sufficient amount in the areas where the studies were conducted.

RVGE	Se	rotype-specific	Study	Country	Ref			
severity	G1	G2	G3	G4	G9	type		
Any severity	75(67,81) †	63(3,88) †	83(<0,100)	48(<0,92)	65(<0,99)	RCT	Multi- country	Vesikari, NEJM, 2006
Hosp and ED visits	95(92,97) †	88(<0,99)	93(49,99) †	89(52,98) †	100(70,100) †	RCT	Multi- country	Vesikari, NEJM, 2006
Hosp and ED visits	89(55,97) †	87(65,95) †	80(64,89) †	ND	ND	PMS	US	Payne, CID, 2015
Severe (VS≥11)	66(28,84) †	77(55,89)†	100(<0,100)	93(29,99) †	83(<0,99)	PMS	Nicaragua	Mast, PIDJ, 2011
Hosp and ED visits	96(79,99) †	72(7,92) †	86(60,95) †	ND	83(17,97) †	PMS	US	Staat, Pediatrics, 2011

Table 1	Serotype-specific efficacy and effectiveness of ROTATEQ® in clinical trials
	and post-marketing studies conducted out of China

RCT: randomized clinical trial; PMS: post marketing study: VS: Vesikari Score is the results of the Vesikari Scoring System, which was developed to evaluate the effectiveness and efficacy of rotavirus vaccines based on the intensity of different AGE symptoms; ND: no data.

† Statistically significant

In the Phase 3 trial that was conducted in China,[20] overall efficacy against RVGE of any severity and severe RVGE caused by any serotype were 69.3% (95%CI: 54.5%-79.7%) and 78.9% (95%CI: 59.1%-90.1%), respectively. Serotype-specific efficacy was also demonstrated against the serotypes G1 (74.4%, 95%CI: 47.8%-88.6%) and G9 (67.4%, 95%CI: 45.2%-81.4%). It could not be demonstrated against the serotypes G2, G3 or G4 because of the very small number of cases caused by any of those three serotypes among

		27
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0	
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024	

vaccinated (3 cases) and unvaccinated infants (8 cases) given the low circulation of these three RV serotypes in China during the study period.

The circulation of RV G2, G3, and G4 serotypes has been described to be decreasing and unpredictable in China since 2009. A sentinel-based surveillance of acute diarrhea indicated that among 2,533 genotyped RV serotypes, G2, G3 and G4 represented an average of 4.5%, 21.1% and <1%, respectively.[21] The previously dominant serotype G3 decreased rapidly from ~60% in 2009/2010 to ~10% in the more recent years.[21] Moreover, some published local studies that assessed the RV serotype distributions among AGE cases in children under 5 years of age in China also indicated unpredictable circulation of G2, G3, G4, ranging from respectively 7.8% to 14.0%, 0.9% to 18.7% and <1% to 1.5 of RVGE cases with the combined circulation of G2/G3/G4 as 12.0% to 27%.[3], [7], [13], [22].In a recent publication, G2, G3, and G4 strains were identified in 12.3% of Chinese children with severe RVGE during the peak season (September 2012 to June 2013).[14]

The Sponsor proposes to use a test-negative study design to assess the serotype-specific effectiveness of ROTATEQ. The test-negative studies are expected to reduce confounding bias because cases and controls have similar symptoms and therefore are likely to have similar care-seeking behaviors and may also be similar with respect to other characteristics, such as age, comorbidities or access to health care. By collecting vaccination data prior to knowledge of the test results, bias in ascertainment of vaccination among cases and controls can be avoided through the test-negative studies.[23], [24], [25], [26], [27] This design had been widely used to evaluate VE of RV vaccines in China,[10] US,[27] Finland,[28] Israel,[29] Japan,[23] Philippines,[30] Portugal,[31] Spain,[32] and Zimbabwe.[33]

6 RESEARCH QUESTIONS AND OBJECTIVES

The aim of this study is to estimate the serotype-specific effectiveness of ROTATEQ® in a large population using a test-negative design.

6.1 **Primary Objectives**

- To assess the effectiveness of ROTATEQ[®] in children treated in the hospital for RVGE due to at least one of the RV serotypes G2/G3/G4.
- To assess the effectiveness of ROTATEQ[®] in children treated in the hospital for RVGE due to at least one of the RV serotypes G1/G2/G3/G4/G9.

	28
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO. (PE STUDIES ONLY):	
EP008011.033	

7 **RESEARCH METHODS**

7.1 Study Design

This study does not involve active administration of ROTATEQ[®]. Under this protocol, all recipients of ROTATEQ[®] received ROTATEQ[®] previously, in the course of ordinary public health practice.

The design is a test-negative case-control. All RVGE cases identified during the study period in the study population, age-eligible to be fully vaccinated with 3 doses of ROTATEQ[®] and receiving treatment for AGE in hospitals with any of RV serotypes G2/G3/G4 (first primary objective) and G1/G2/G3/G4/G9 (second primary objective) identified will be "cases". All RV negative AGE cases receiving treatments in hospitals identified from the same data source over the same study period in children, age-eligible for vaccination with ROTATEQ[®] will be "controls".

The study will enroll eligible children during four RV peak seasons. One interim analysis by a third party is planned after the third season with all available data. The interim analysis results will be submitted to an external DMC for review. The DMC will make recommendations to stop or continue the enrollment, based on prespecified criteria that will be outlined in the DMC charter.

7.2 Setting

The study population is the children age-eligible to be fully vaccinated with 3 doses of ROTATEQ® and receiving treatment for AGE in hospitals.

Age-eligible: to be fully vaccinated with 3 doses of ROTATEQ® denotes children who could have received 3 doses of ROTATEQ® + 14 days to develop immunity based on following criteria:

- Minimum age of 16 weeks at the time of AGE onset; and
- Maximum age of 12 weeks (upper age limit for dose 1) when ROTATEQ® was launched in the respective hospital catchment area.

AGE is defined as 3 or more watery or looser than normal stools within 24 hr period and/or forceful vomiting. The onset of gastroenteritis should be \leq 14 days prior to admission.

Receiving treatment for AGE in hospitals denotes:

- Admission to the inpatient ward due to AGE; or
- Received intravenous (IV) rehydration treatment for at least 2 consecutive calendar days due to AGE in the outpatient hospital setting.

Study duration

The study will start at the date of study initiation in the selected hospitals where ROTATEQ® has been launched and conducted for four or less RV peak seasons.

Inclusion Criteria

All children, age-eligible to be vaccinated with ROTATEQ[®] (infants not older than 12 weeks when ROTATEQ[®] was introduced in the catchment areas of the selected hospitals), presenting with symptoms of severe AGE to one of the selected hospitals and whose parents signed an informed consent.

Exclusion Criteria

None.

7.3 Variables

7.3.1 Exposure

The study exposure of interest is ROTATEQ® vaccination status. However, this study does not involve active administration of ROTATEQ®. The study will include children who received ROTATEQ® in routine immunization practice.

Children are considered "vaccinated" if they have received all 3 doses of ROTATEQ® at least 14 days before the onset of AGE. Children are considered "not vaccinated" if they haven't received any dose of ROTATEQ®. Those who received an incomplete ROTATEQ® schedule or a mixed schedule with ROTATEQ® and other RV vaccines will be excluded from the main analysis.

7.3.2 Outcomes

The study outcome is AGE receiving treatments in hospitals.

For the first primary objective, a child with RVGE receiving treatment in hospitals and positive for at least one of the serotypes G2/G3/G4 is considered a "case".

For the second primary objective, a child with RVGE receiving treatments in hospitals positive for at least one of the serotypes G1/G2/G3/G4/G9 is considered a "case".

	50
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY):	
EP008011.033	

Children are considered a "control" both for the first and second primary objectives if they have RV negative AGE receiving treatments in hospitals.

Any herein described health outcomes, collected per the protocol, will be summarized as part of any interim analysis (if required) and in the final study report in addition to being reported in real-time as individual AE/s if the criteria in section 9 are met. Refer to section 9 for AE reporting requirements and procedures.

7.3.3 Covariates

- Child's gender;
- Child's age;
- Residence location;
- Symptom Onset Seasons;
- Birth season;
- Region of study hospital;
- Clinical setting;
- Parents education level;

Analyses will be carried out using the available data. A participant with missing data on one variable will be used only in calculations that do not involve that variable. This allows analysis with larger sample sizes than when using complete datasets on all variables.

7.4 Data Sources

The primary data collection (PDC) includes lab testing results and information collected by interviews while secondary data collection (SDC) includes the data collection from EMR and vaccination records. AGE cases receiving treatments in hospitals will be identified from selected hospitals. Stool samples of AGE cases will be collected for RV antigen testing and samples of RVGE cases will undergo serotype characterization. Demographics and clinical information will be collected through interviews (include parents' education level) and/or medical charts, and the vaccination status will be collected from vaccination cards or from immunization registers/ application programs (APPs) if vaccination cards are not available. Vaccination cards are not available.

Hospital selection criteria:

Hospitals are eligible to be selected if they meet the following criteria:

- Expected to have at least 15% ROTATEQ® coverage in the catchment area;
- Able to collect ~100 stool samples per year from children with AGE receiving treatment in hospitals;
- Able to collect demographic and clinical information relevant to the study;
- Able to determine RV vaccination status of children with AGE either from vaccination cards or by linking to regional immunization registers.

The number of selected hospitals needs to be sufficient to ensure that the estimated sample size can be reached and depends also on the expected ROTATEQ® coverage in the hospital catchment areas. At least 30 hospitals are planned to participate to the study.

Regional immunization register and vaccination cards

- For each vaccine recipient, vaccination is required to be recorded in both the regional immunization register and the vaccination cards, including recipient's name, gender, personal ID, birth date, resident address, date of vaccination, vaccine name, injection site, vaccine lot number, dose number, manufacturer, and name of the vaccination clinic. The immunization register is maintained by the Center for Disease Control and Prevention (CDC) at national, provincial and city level according to their jurisdictions, while parents of children hold the vaccination cards as the proof of vaccination.
- There are also officially authorized mobile APPs available for parents in some regions/cities of China to get access to the vaccination information of child without direct visit to regional immunization register or carrying the vaccination card all the time.

7.4.1 Study Procedures

General procedure

This study does not involve active administration of ROTATEQ[®]. The study protocol will be submitted for approval by the institutional review board.

	32
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO .: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO. (PE STUDIES ONLY):	
EP008011.033	



	It (Garst I) cuse		Iotui
Vaccinated	а	С	a+c
Unvaccinated	b	d	b+d
Total	a+b	c+d	п

Figure 1 Flow chart for post-marketing study to assess serotype-specific effectiveness of ROTATEQ® against RVGE receiving treatments in hospitals and tested positive for at least one of the RV serotypes G2/G3/G4

33
PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
CORE DRC APPROVAL DATE: 7-JUNE-2024



Figure 2 Procedures of eligible patients enrollment and data generation in the present study

The primary data collection procedure

- Children age-eligible to be fully vaccinated with 3 doses of ROTATEQ® and receiving treatment for AGE in hospitals will be eligible for enrollment in the study and recorded in a enrollment log.
- After informing the parents about the study, the participating practitioner will check the eligibility of the child to participate in the study and will request the parent to sign an informed consent form.
- Once the informed consent has been signed, parents of the enrolled children will be interviewed with the use of a standardized case report form. Additional medical information will be abstracted from medical charts by trained staff if needed. The collected information includes demographics (e.g., gender, date of birth, educational status of the parents) and clinical characteristics (e.g., signs/symptoms, date of symptom onset, date of diagnosis). RV vaccination (ROTATEQ®, LLR and other RV vaccines) status will be collected from vaccination cards/immunization registers/APPs. After enrollment, fresh, whole stool samples will be collected per the routine medical practice.
- All stool samples will be stored at the appropriate temperature until testing is performed and transported to the laboratory according to the samples management guidelines. These guidelines will be developed by the laboratory in collaboration with MSD China.
- A standardized method and operation procedure will be adopted by a central laboratory for RV testing and characterization of serotypes and will be validated before initiating the primary data collection. Group A RV antigens will be detected directly in stool samples by using ELISA assay. For ELISA-positive samples, multiplex reverse-transcription polymerase chain reaction assays will be used for further genotyping of the strains.
- AGE cases without RV test results and RVGE cases that do not contain any of the serotypes G1/G2/G3/G4/G9 or that are untypable will be excluded from the data analysis.

Vaccination status

- Vaccination information will be extracted from vaccination cards, and if not available, it will be extracted from the immunization registers or eligible APPs. For children whose vaccination information will be collected from vaccination cards, parents of the included child will be asked to provide the photograph/copy of the vaccination card cover page and the RV vaccination entry of their child.
- Vaccination information can also be extracted from the immunization registers based on child's name, gender, birth date, parents' name and residence address. Regional

PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	

practitioner or trained staff from regional CDC will take this responsibility. If there is more than one entry with the same name, gender, and birth date, parents' name and resident's address will be added stepwise to remove the duplication due to individuals with the same name, gender and birth date.

35

Test-negative case control analysis

- For the first primary objective, the numbers of vaccinated RVGE (G2/3/4) cases (a), unvaccinated RVGE (G2/3/4) cases (b), vaccinated RV (-) AGE cases (c) and unvaccinated RV (-) AGE cases (d) will be summed up based on RV testing, G/P genotyping results and ROTATEQ® vaccination histories for each eligible AGE case. The numbers of a, b, c, and d will be entered into the table listed in Figure 1. The ratio of RVGE (G2/3/4) cases (cases) to RV (-) AGE cases (controls) is expected to be around 1:30, depending on the available number of controls.
- For the second primary objective, the RVGE (G1/2/3/4/9) cases will be considered as cases and the ratio to RV (-) AGE cases (controls) is expected to be around 1:3, depending on the available number of controls.

7.5 Study Size

Only children (cases and controls) who are age-eligible to be fully vaccinated with 3 doses of ROTATEQ® and receiving treatment for AGE in hospitals are eligible to be included in the study. That means, only children aged at least 16 weeks (minimum age for full completion of 3-dose schedule + 2 weeks for immunity to develop) will be included.

The test-negative case-control study is designed to estimate the ROTATEQ® vaccine effectiveness (VE) against RVGE due to RV serotypes G2/G3/G4 (first primary objective) and the ROTATEQ® VE against RVGE due to RV serotypes G1/G2/G3/G4/G9 (second primary objective). Based on current enrollment rate, approximately 7,393 (maximum 7,600) age-eligible AGE cases are estimated to be included by the end of the fourth season.

For the first primary objective, assuming RVGE representing 33% of all cause AGE in the peak season (October to April of the following year),37 4.5% of RVGE being due to serotypes G2/G3/G4, 97% of enrolled AGE cases having complete rotavirus vaccination information, 20% of them having been vaccinated with other rotavirus vaccines, 85 cases of RVGE due to serotypes G2/G3/G4 are expected to be accumulated for inclusion in the analysis. Assuming a 25% ROTATEQ® coverage according to the recommended schedule in selected hospital catchment areas during the study period, a VE of 60% and 30 controls available by case, the estimated study sample size (7,393) is expected to provide around 80% probability to observe a lower bound of the 95% CI of VE >0%, 85% probability to observe a point estimate of VE >50%.

For the second primary objective, assuming 50% of RVGE are due to serotypes G1/G2/G3/G4/G9, 946 cases due to G1/G2/G3/G4/G9 are expected for inclusion in the final analysis. Assuming a VE of 60% and 3 controls available by case, the estimated sample size

	30
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	

(7,393) will provide >99% probability to observe a lower bound of 95% CI of VE >0%, >99% probability to observe a point estimate of VE >45%, or 99% probability to observe a point estimate of VE >50%.

By the time of interim analysis at the end of the third season, based on the assumptions described above, 5,200 AGE cases are expected to be included in the study, 59 of which are due to G2/G3/G4 and 665 are due to G1/G2/G3/G4/G9. For the first primary objective of VE against RVGE due to serotypes G2/G3/G4, there will be a probability of 65%, 81%, or 73% to observe a lower bound of the 95% CI of VE >0%, a point estimate of VE > 45%, or a point estimate of VE >50%, respectively. For the second primary objective of VE against RVGE due to serotypes G1/G2/G3/G4/G9, there will be a probability of >95% to observe a lower bound of the 95% CI of VE >0%, a point estimate of VE > 45%, or a point estimate of VE >0%, >99% probability to observe a point estimate of VE >45%, or 99% probability to observe a point estimate of VE >50%, respectively.

The current assumptions used for sample size estimations are based on previously collected samples, which may change depending on the proportion of RV positive samples among all cause AGE as well as on the proportion of RV G2/G3/G4 specific cases. Table 2 presents the total number of cases needed to provide 80% probability to observe a lower bound of the 95% CI of VE >0% for each primary objective, under varying assumptions of ROTATEQ® coverage and expected VE. For the first primary objective, the calculations assume that 30 controls will be available for each G2/G3/G4 case and for the second primary objective, the calculations assume 1, 2, or 3 controls available per G1/G2/G3/G4/G9 case.

1 2 5				
ROTATEQ [®] coverage (%)	Expected vaccine effectiveness (%)	Number of G2/G3/G4 cases (combined, case: control ratio 1:30)	Number of G1/G2/G3/G4/G9 cases (combined, case: control ratio 1:1/1:2/1:3)	
20	50	156	270/214/194	
20	60	100	172/138/125	
20	70	67	115/93/84	
25	50	131	226/180/164	
25	60	84	144/116/105	
25	70	56	97/78/70	
30	50	116	198/159/144	
30	60	74	126/102/92	
30	70	49	84/68/62	

Table 2Total number of cases needed to provide 80% probability to observe a lower95% confidence bound of VE greater than zero for the first primary objective and second
primary objective

	57
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	

Table 3 presents the probability of observing a point estimate of VE >45% and >50% for the first primary objective and second primary objective respectively in the final and interim analysis, under varying assumptions of number of cases in interim/final analysis and expected VE. For the first primary objective, the calculations assume 30 controls available by G2/G3/G4 case and for the second primary objective, the calculations assume 3 controls available by G1/G2/G3/G4/G9 case.

	ROTATEQ [®] coverage (%)	Expected vaccine effectiveness (%)	Probability of observing a point estimate of VE > 45%	Probability of observing a point estimate of VE > 50%
Based on 85	25	50	63	52
G2/G3/G4 cases	25	60	85	76
control ratio 1:30)	25	70	97	94
Based on 946	25	50	83	52
G1/G2/G3/G4/G9 cases (combined	25	60	>99	99
case: control ratio 1:3)	25	70	>99	>99
Based on 59	25	50	63	53
G2/G3/G4 cases	25	60	81	73
control ratio 1:30)	25	70	95	91
Based on 665	25	50	78	50
G1/G2/G3/G4/G9 cases (combined	25	60	>99	99
case: control ratio 1:3)	25	70	>99	>99

Table 3Probability of observing a point estimate of VE for the first primary objective
and second primary objective in final analysis and interim analysis

7.6 Data Management

All data collected for the study should be recorded accurately, promptly, and legibly. For primary data collection, the investigator or qualified designee is responsible for recording and verifying the accuracy of subject data. For data not obtained from a primary source (i.e., secondary data, such as claims and electronic health records), the investigator is responsible for reviewing data quality and relevance to the best of the investigator's knowledge. By signing this protocol either electronically or written, the investigator confirms that the quality and relevance of data has been assessed to meet the minimum requirements for all study objectives.

	50
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	

If this study has been outsourced, the institutional policies of the supplier should be followed for development of data management plans. However, the supplier should ensure compliance with Good Pharmacoepidemiology Practice, and all applicable federal, state, and local laws, rules and regulations relating to the conduct of the study.

Data Management Software and Hardware:

EDC and SAS 9.4

Description of Data Preparation and Methods for Data Retrieval and Collection:

All data management activities including data capture, data storage, data cleaning, data security, and system backup processes will be undertaken by qualified personnel and will follow all procedures detailed in a separate "Data Management Plan".

The Study will comply with Good Pharmacoepidemiology Practice (GPP), and all applicable federal, state, and regional laws, rules and regulations relating to the conduct of the study.

7.7 **Programming Quality**

This study will incorporate the following quality checks for data analysis and reporting programming:

- Creating a program requirements and specification document (PRS)
- Developing and testing of statistical programs which includes ensuring the programs run successfully and all output are reviewed to ensure they meet the criteria included in the (PRS). This includes validating that all inputs (metadata or parameter values) are correctly specified in the programs and are consistent with the PRS.
- Independent Review and Testing, conducted by a second programmer to ensure that the input and outputs of the programs created by the first programmer meet the documented PRS. This includes the following 2 activities:
 - Review of code to ensure the program aligns with the PRS
 - Execution of code and review of results for some or all scenarios

And may include the following activity:

- Parallel programming of a small piece of critical code
- Independent Double Programming, conducted by second programmer. After programming is completed, the programs and results of the second programmer and compared to those of first programmer to ensure consistency. If discrepancies are found, the programmers will discuss and repeat steps until consistency is achieved.

	35
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	

• Review of outputs/results to ensure accuracy and format of each deliverable.

7.8 Data Analysis

The study includes one interim analysis (planned after the third season) and a final analysis at the end of the study with data from the entire study period over four seasons

Descriptive analysis

A descriptive analysis of the distribution of values observed for each variable will be provided. Search for outliers, logical errors and necessary corrections will be made. The following indicators will be computed (for each hospital and by year, if relevant):

- Number of AGE cases in children age-eligible to be vaccinated with ROTATEQ[®];
- Number of RVGE cases in children age-eligible to be vaccinated with ROTATEQ[®];
- Number of G1, G2, G3, G4, G9 AGE cases (by each serotype and in aggregate) in children age-eligible to be vaccinated with ROTATEQ[®].

The study will also describe baseline characteristics (gender, age, locations and month of onset) of cases and controls.

Vaccine effectiveness (VE)

The VE will be estimated among children eligible to be vaccinated with ROTATEQ®. In order to estimate the VE against RVGE receiving treatments in hospitals, logistic regression will be fitted for each primary objective to estimate the odds ratio of RVGE associated with ROTATEQ® vaccination (defined as three doses of ROTATEQ® according to the recommended schedule plus 14 days), adjusted for potential confounders such as age, gender, calendar time of onset and location (urban/rural) (more details will be provided in the Statistical Analysis Plan). The VE will be calculated as (1-odds ratio)×100%.

VE will be stratified and adjusted if numbers allow according to age, gender, calendar time of onset, location (urban/rural) and hospital.

For the first primary objective, if the number of controls allows, up to 30 controls will be matched by age, gender, calendar time and parents' education level to each case. For the second primary objective, if the number of controls allows, up to 3 controls will be matched by age, gender, calendar time and parents' education level to each case. The matching criteria and case control ratio will be further described in the Statistical Analysis Plan. For sensitivity analysis, VE will be estimated among children eligible to be vaccinated with ROTATEQ[®].

	40
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	

Besides assessing the VE predefined in the study objectives, the data might be used for other research purposes.

7.9 Quality Control

By signing this protocol, all parties agree to following applicable standard operating procedures (SOPs). All parties also agree to ensuring all existing and new study personnel are appropriately trained to ensure the study is conducted and data are generated, documented, and reported in compliance with the protocol, Good Pharmacoepidemiology Practice (GPP), Good Pharmacovigilance Practices (GVP), and all applicable federal, state, and local laws, rules and regulations. All parties should maintain transparency and open communication in order to effectively manage the study and proactively mitigate any risks.

The Sponsor may conduct routine or for-cause audits to ensure oversight and conduct of the study are completed in accordance with the protocol, quality standards (e.g. GPP and GVP), and applicable laws and regulations. If a significant quality issue (SQI) is identified at any time during the conduct of the study, it must be escalated to the Sponsor immediately. A SQI is any issue with the potential to negatively impact, either directly or indirectly, the rights, safety and well-being of patients or study participants and/or the integrity of the data. In the event an audit or SQI results in corrective or preventive actions, all parties are expected to appropriately implement the action plan in a timely manner.

The investigator will supervise the selected hospitals using the standardized method to collect, store and ship stool samples to a central lab which is qualified for Group A RV antigen testing using ELISA kit for the virus identification and Multiplex RT-PCR for characterizing G and P types.

For vaccination status collected from regional immunization registers/APPs, two trained persons will cross check linkage results and double entry.

For vaccination status collected from vaccination cards, the information will be validated by reviewing the photographs of the vaccination cards.

7.10 Limitations of the Research Methods

The sample size calculation is based on several assumptions. The sample size might be lower than expected due to the uncertainty of those assumptions. There is a risk that the number of RVGE cases due to serotypes G2/G3/G4 will be lower than expected due to a lower than expected circulation of these strains in the upcoming years. Also ROTATEQ® vaccine coverage might be lower than expected in the selected hospital catchment areas or other rotavirus vaccines might be used more frequently making a 1 to 30 ratio impossible and resulting in decreased statistical power. Beyond 4 controls per case, gain in statistical power is marginal; however, is needed in this study due to limited number of cases.

As ROTATEQ® is a type 2 vaccine, not covered by the Chinese Health Insurance, there may be a difference in the socioeconomic status between vaccinated and unvaccinated children,

		41
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0	
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024	
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033		

resulting in differences in their health care seeking behavior. Children with AGE from families with higher socio-economic status may be more likely to be admitted to hospitals compared to children from families with lower socio-economic status. Therefore, AGE cases occurring in children from families with lower socio-economic status (and thus not vaccinated with ROTATEQ®) might be missed.

7.11 Other Aspects

Not applicable

8 PROTECTION OF HUMAN SUBJECTS

This is a non-interventional study and data will be de-identified at the time of analysis. The privacy of all participants will be well protected and database management will follow local requirements.

All demographic and clinical information for each eligible AGE case, as well as RV testing and genotyping results from their stool samples are generated during the conduct of the prospective AGE study. The RV vaccination information both from regional immunization registers and vaccination cards will be tracked, collected, stored and used by the study staff of the prospective study and will not be provided to entities outside the study.

The study protocol will be submitted for review and approval by an Independent Ethics Committee.

8.1 Informed Consent

Consent must be documented by the subject's dated signature or by the subject's legally acceptable representative's dated signature on a consent form along with the dated signature of the person conducting the consent discussion.

A copy of the signed and dated consent form should be given to the subject before participation in the study.

The initial informed consent form, any subsequent revised written informed consent form and any written information provided to the subject must receive the IRB/ERC's approval/favorable opinion in advance of use. The subject or his/her legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the subject's willingness to continue participation in the study. The communication of this information will be provided and documented via a revised consent form or addendum to the original consent form that captures the subject's dated signature or by the subject's legally acceptable representative's dated signature.

Specifics about a study and the study population will be added to the consent form template.

	42
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	

The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations and Sponsor requirements.

The informed consent will comply with ethic's committee requirements, applicable laws and regulations and Sponsor requirements. Only data from children whose parents provide informed consent to participate in the study will be collected.

Investigators shall ensure that personal identifiers will be removed from any study files that are accessible to non-study personnel in accordance with applicable laws and regulations. Whenever feasible, study files should be coded and stripped of personal identifiers, and code keys should be stored separate from study files.

9 MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE REACTIONS

Adverse Event (AE) and Product Quality Complaint (PQC) Reporting Language for Non- Interventional Study Protocols

Introduction

This is a non-interventional study being conducted within routine medical practice, which includes primary data collection and use of secondary data collected by healthcare professionals for other purposes. All direction for medication usage is at the discretion of a physician in accordance with usual medical practice. No administration of any therapeutic or prophylactic agent is required in this protocol.

9.1 Adverse Event and Product Quality Complaint Reporting

9.1.1 Investigator Responsibility

Primary Data Collection (Laboratory testing and information collected by interviews): if adverse events (AEs) or product quality complaints (PQCs) are identified following use of ROTATEQ[®] or any other Sponsor product, then the AE* and/or PQC must be reported according to Table 4. The investigator must evaluate each SAE for causality and record causality on the report form for each SAE and NSAR reported.

<u>Secondary Data Collection (SDC)</u>: The SDC includes the data collection from EMR and vaccination records. Although adverse events (AEs) and product quality complaints (PQCs) are not actively solicited in this study, there are certain circumstances in which individual AEs and/or PQCs will be reported. For example, during review of medical records or physician notes (paper or electronic), to collect data as required by the protocol, if an NSAR, SAR, special situation or PQC to ROTATEQ[®] or any other Merck product is identified in the secondary data source being reviewed, then the AE/PQC must be reported according to Table 4.

		+5
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0	
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024	
EPIDEMIOLOGY NO. (PE STUDIES ONLY): EP008011.033		

Note: For secondary data collection, explicit and definitive notation (by a healthcare provider) of a causal relationship with a product (in the medical records or other secondary data being reviewed) is required for an AE to be considered an NSAR/SAR.

*For the purposes of this protocol, the following types of AEs are reportable (refer to section 9.2 for definitions):

- Serious adverse events (SAEs), including death due to any cause (*primary data collection*)
- Serious adverse reactions (SARs), including death (*secondary chart review*)
- Non-serious adverse reactions (NSARs)
- Special situations

AEs, PQCs, and AEs that occur in combination with PQCs, or spontaneously reported events, should all be captured using the AE/PQC report form for each patient and reported according to Table 4.

If any health outcomes are described in section 7.3.2. they must be assessed for AE reportability according to Table 4 (refer to section 4.1 for more information).

Note: The primary objective of the study is to assess the effectiveness of ROTATEQ[®] in children who, prior to enrollment, are being treated in the hospital for RVGE due to at least one of the RV serotypes G2/G3/G4 or G1/G2/G3/G4/G9. ROTATEQ[®] vaccination data will be collected from secondary data sources. The study outcomes include AGE, including RV positive AGE and RV negative AGE. Therefore, individual case safety reports for AGE (occurring prior to enrollment) will not be collected within the context of the study (as it is not possible to retrospectively assess these cases for causality) unless there is explicit and definitive notation (by a health care provider) of a causal relationship between AGE and ROTATEQ[®] (or other Merck product) within the secondary data being reviewed.

For primary data collection, ROTATEQ[®] vaccination data will not be solicited and AGE cannot be retrospectively assessed, therefore AGE will only be reported as an individual case if the Investigator happens to become aware of AGE that has a causal relationship to ROTATEQ[®] or other Merck product. AGE will be summarized in the final study report.

AEs, PQCs, and AEs that occur in combination with PQCs, or spontaneously reported events, should all be captured using the AE/PQC report form for each patient and reported according to Table 4.

	44
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	

Table 4AE and PQC Reporting Timeframes and Process for Investigators and
Suppliers

AEs AND PQCs	INVESTIGATOR TIMEFRAMES	SUPPLIER TIMEFRAMES
	Investigator to Supplier [1], [2]	Supplier to Sponsor [3]
Primary data collection: SAE regardless of causality Serious Special Situation, regardless of causality	24 hours from receipt	24 hours from time of receipt from investigator
Secondary data collection: SAR Serious Special Situation, regardless of causality	24 hours from receipt	24 hours from time of receipt from investigator
NSAR Non-serious Special Situation, regardless of causality	10 CD from receipt	24 hours from time of receipt from investigator
PQC with or without an AE (SAE/SAR/NSAR/Special situation)	24 hours from receipt	24 hours from time of receipt from investigator
Follow-up to any AE/PQC-submit using above	e timeframes	
BD-Business Day; CD-Calendar Day		
Non-Sponsor Products: If the investigator elects to submit AEs/PQCs for non-Sponsor		

products, they should be reported to the market authorization holder (MAH) for that product or to the health authority according to the institution's policy or local laws and regulations.

[1] Investigator to Supplier: AEs and PQCs for Sponsor study product and other Sponsor products are submitted to Supplier via fax or secure email.

[2] Supplier enters AEs for Sponsor study product into study database (or equivalent repository) for tabulation in study report

[3] Supplier to Sponsor: Supplier submits AEs and PQCs for Sponsor study product and *other* Sponsor products to Sponsor for reporting to worldwide regulatory agencies as appropriate

Submitting AEs and PQCs to MSD ^{CCI}	: All AEs and PQCs must be
submitted to CCI	in English/Chinese using the
AE/POC reporting form.	

9.1.2 Study Report

The final study report, and any planned interim analysis, will include a summary of all reported AEs and special situations collected for ROTATEQ[®] and will be provided to regulatory agencies by the sponsor as required.

PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO. (PE STUDIES ONLY): EP008011.033	

9.1.3 **Periodic Safety Update Reports**

Any relevant safety information will be summarized and the Sponsor will include in the appropriate Periodic Safety Update Report (PSUR)/Periodic Benefit Risk Evaluation Report (PBRER) and/or Development Safety Update Reports (DSUR) if required.

9.2 Definitions

9.2.1 Adverse Event (AE)

Any untoward medical occurrence in a patient or clinical investigation subject administered sponsor's product and which does not necessarily have to have a causal relationship with this product. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the product, whether or not considered related to the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the product, is also an adverse event.

9.2.2 Adverse Reaction (AR); also referred to as Adverse Drug Reaction (ADR)

An AE which has a causal relationship with the product, that is, a causal relationship between the product and the adverse event is at least a reasonable possibility.

9.2.3 Serious Adverse Event (SAE)/Serious Adverse Reaction (SAR)

An adverse event or adverse reaction that results in death, is life threatening, results in persistent or significant disability/incapacity, requires inpatient hospitalization, prolongation of existing inpatient hospitalization, is a congenital anomaly/birth defect, or is another important medical event. Other important medical events that may not result in death, may not be life-threatening, or may not require hospitalization may be considered an SAE/SAR when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the other outcomes listed previously. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home and blood dyscrasias or convulsions that do not result in inpatient hospitalization.

9.2.4 Non-serious Adverse Reaction (NSAR)

An adverse reaction that does not meet any of the serious criteria in 7.2.3.

9.2.5 Special Situations

The following special situations are considered important safety information and must be reported, regardless of seriousness or causality, if the investigator becomes aware of them:

• Overdose

PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO. (PE STUDIES ONLY): EP008011.033	

- Exposure to product during pregnancy or lactation
- Lack of therapeutic effect
- Off-label use, medication error, misuse, abuse, or occupational exposure
- Suspected transmission via a medicinal product of an infectious agent
- Unexpected Therapeutic Benefit/Effect

9.2.6 Product Quality Complaint (PQC)

Any communication that describes a potential defect related to the identity, strength, quality, purity or performance of a product identified by an external customer. This includes potential device or device component malfunctions.

9.2.7 Malfunction

The failure of a device (including the device component of a combination product) to meet its performance specifications or otherwise perform as intended. Performance specifications include all claims made in the labeling for the device.

9.2.8 Sponsor's product

Sponsor's product includes any pharmaceutical product, biological product, device, diagnostic agent or protocol-specified procedure, whether investigational (including placebo or active comparator product) or marketed, manufactured by, licensed by, provided by or distributed by the Sponsor for human use.

9.2.9 Causality Assessment

A causality assessment is the determination of whether or not there is at least a reasonable possibility that a product caused the adverse event. Causality must be recorded on the AE form by the investigator for each reported event in relationship to a Sponsor's product.

Primary Data Collection

The assessment of causality is to be determined by an investigator who is a qualified healthcare professional according to his/her best clinical judgment. The following criteria should be used as guidance (not all criteria must be present to be indicative of causality to a Sponsor's product): There is evidence of exposure to the Sponsor's product; the temporal sequence of the AE onset relative to the administration of the Sponsor's product is reasonable; the AE is more likely explained by the Sponsor's product than by another cause.

	17
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO. (PE STUDIES ONLY): EP008011.033	

Secondary Data Collection

Only AEs with an explicit and definitive notation (by a healthcare provider) of a causal relationship with a product in the medical records or other secondary data being reviewed should be reported as NSAR/SARs. During review of secondary data, causality should never be assigned retrospectively.

9.3 AE/PQC Reconciliation

Reconciliation will be performed between the safety database and study data to ensure all reportable AEs and PQCs were reported and received. Starting from when the first patient is enrolled through the end of data collection, all AEs and PQCs will be reconciled on a periodic basis.

9.4 Study Governance and Oversight

A Data Monitoring Committee (DMC) will monitor safety and effectiveness data from this study. The voting members of the committee are external to the Sponsor. The members of the DMC must not be involved with the study in any other way (e.g., they cannot be study Investigators) and must have no competing interests that could affect their roles with respect to the study. The DMC will consist of 3 members including one pharmacoepidemiologist, one vaccinologist/virologist/pediatrician and one statistician. The DMC will review the available data from the study including the interim analysis data. The pre-specified criteria for the interim analysis will be defined in the DMC charter.

Specific details regarding the DMC will be described in a separate Data Monitoring Committee Charter.

DMC recommendations will be communicated to business partners or consortia members per collaboration or consortia agreement.

10 PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS

The primary results of this research study will be externally disseminated in a manuscript submitted to a peer-reviewed, scientific journal, abstract/presentation at a scientific conference or symposium, or results posted on the EU PAS Register. Any publication related to the study will need to be reviewed/approved by the Sponsor prior to submitting results externally. Any publication resulting from this work will adhere to the procedures and prespecified analysis plans within this protocol.

PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO (PE STUDIES ONLY) · EP008011.033	

11 REFERENCES

- [1] Troeger C, Khalil IA, Rao PC, Cao S, Blacker BF, Ahmed T, et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr. 2018 Oct;172(10):958-65.
- [2] World Health Organization. Le point sur les vaccins antirotavirus [Rotavirus vaccines: an update]. Wkly Epidemiol Rec. 2009 Dec 18;84(51-52):533-7.
- [3] Zhang J, Liu H, Jia L, Payne DC, Hall AJ, Xu Z, et al. Active, population-based surveillance for rotavirus gastroenteritis in Chinese children: Beijing Municipality and Gansu Province, China. Pediatr Infect Dis J. 2015 Jan;34(1):40-6.
- [4] Wu D, Yen C, Yin ZD, Li YX, Liu N, Liu YM, et al. The public health burden of rotavirus disease in children younger than five years and considerations for rotavirus vaccine introduction in China. Pediatr Infect Dis J. 2016 Dec;35(12):e392-8.
- [5] China Center for Disease Control and Prevention. Annual report on surveillance of infectious disease in China, 2019. Beijing (China): China Center for Disease Control and Prevention (CDC); 2019.
- [6] Cunliffe NA, Bresee JS, Hart CA. Rotavirus vaccines: development, current issues and future prospects. J Infect. 2002;45:1-9.
- [7] Li J, Zhang Y, Yang Y, Liang Z, Tian Y, Liu B, et al. Effectiveness of Lanzhou lamb rotavirus vaccine in preventing gastroenteritis among children younger than 5 years of age. Vaccine. 2019;37:3611-6.
- [8] Zhang H, Lai X, Mak J, Sriudomporn S, Zhang H, Fang H, et al. Coverage and equity of childhood vaccines in China. JAMA Netw Open. 2022 Dec 9;5(12):e2246005.
- [9] Fu C, Dong Z, Shen J, Yang Z, Liao Y, Hu W, et al. Rotavirus gastroenteritis infection among children vaccinated and unvaccinated with rotavirus vaccine in southern China: a population-based assessment. JAMA Netw Open. 2018 Aug 31;1(4):e181382.
- [10] Fu C, He Q, Xu J, Xie H, Ding P, Hu W, et al. Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children. Vaccine. 2012;31:154-8.
- [11] Fu C, Tate JE, Jiang B. Effectiveness of Lanzhou lamb rotavirus vaccine against hospitalized gastroenteritis [letter to the editor]. Hum Vaccin 2010;6(11):953.

08PSHJ

Confidential

		49
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO .: V260-077/V6.0	
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024	
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033		

- [12] Fu C, Wang M, Liang J, He T, Wang D, Xu J. Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study. Vaccine. 2007;25:8756-61.
- [13] Zhang S, Yin J, Yang J, Tian L, Li D, Zhang Q, et al. Epidemiology and genetic diversity of group A rotavirus in acute diarrhea patients in pre-vaccination era in southwest China. J Med Virol. 2017;89:71-8.
- [14] Xia S, Du J, Su J, Liu Y, Huang L, Yu Q, et al. Efficacy, immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus vaccine (LLR3) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial. Vaccine. 2020;38:7393-400.
- [15] U.S. Product Circular: Solution for oral administration RotaTeq (rotavirus vaccine, live, oral, pentavalent, MSD): Apr 2022.
- [16] Vesikari T, Matson DO, Dennehy P, van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354(1):23-33.
- [17] Mast TC, Khawaja S, Espinoza F, Paniagua M, Del Carmen LP, Cardellino A, et al. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. Pediatr Infect Dis J. 2011 Nov;30(11):e209-15.
- [18] Payne DC, Selvarangan R, Azimi PH, Boom JA, Englund JA, Staat MA, et al. Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013. Clin Infect Dis. 2015 Dec 15;61(12):1792-9.
- [19] Staat MA, Payne DC, Donauer S, Weinberg GA, Edwards KM, Szilagyi PG, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics 2011;128:e267-e275.
- [20] Mo Z, Mo Y, Li M, Tao J, Yang X, Kong J, et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine. 2017 Oct 13;35(43):5897-904.
- [21] Yu J, Lai S, Geng Q, Ye C, Zhang Z, Zheng Y, et al. Prevalence of rotavirus and rapid changes in circulating rotavirus strains among children with acute diarrhea in China, 2009-2015. J Infect. 2019;78:66-74.
- [22] Dian Z, Fan M, Wang B, Feng Y, Ji H, Dong S, et al. The prevalence and genotype distribution of rotavirus A infection among children with acute gastroenteritis in Kunming, China. Arch Virol. 2017;162:281-5.

50
PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
CORE DRC APPROVAL DATE: 7-JUNE-2024

- [23] Araki K, Hara M, Tsugawa T, Shimanoe C, Nishida Y, Matsuo M, et al. Effectiveness of monovalent and pentavalent rotavirus vaccines in Japanese children. Vaccine. 2018;36:5187-93.
- [24] Doll MK, Morrison KT, Buckeridge DL, Quach C. Two birds with one stone: estimating population vaccination coverage from a test-negative vaccine effectiveness case-control study. Clin Infect Dis. 2016 Oct 15;63(8):1080-6.
- [25] Haber M, Lopman BA, Tate JE, Shi M, Parashar UD. A comparison of the testnegative and traditional case-control study designs with respect to the bias of estimates of rotavirus vaccine effectiveness. Vaccine. 2018;36:5071-6.
- [26] Haber M, Lopman BA, Tate JE, Shi M, Parashar UD. Effect of propensity of seeking medical care on the bias of the estimated effectiveness of rotavirus vaccines from studies using a test-negative case-control design. Vaccine. 2019;37:3229-33.
- [27] Tate JE, Patel MM, Cortese MM, Payne DC, Lopman BA, Yen C, et al. Use of patients with diarrhea who test negative for rotavirus as controls to estimate rotavirus vaccine effectiveness through case-control studies. Clin Infect Dis. 2016;62(S2):S106–14
- [28] Hemming-Harlo M, Vesikari T, Uhari M, Renko M, Salminen M, Torcel-Pagnon L, et al. Sustained high effectiveness of RotaTeq on hospitalizations attributable to rotavirus-associated gastroenteritis during 4 years in Finland. J Pediatric Infect Dis Soc. 2017 Dec;6(4):317-23.
- [29] Muhsen K, Anis E, Rubinstein U, Kassem E, Goren S, Shulman LM, et al. Effectiveness of rotavirus pentavalent vaccine under a universal immunization programme in Israel, 2011-2015: a case-control study. Clin Microbiol Infect. 2018;24:53-9.
- [30] Lopez AL, Daag JV, Esparagoza J, Bonifacio J, Fox K, Nyambat B, et al. Effectiveness of monovalent rotavirus vaccine in the Philippines. Sci Rep. 2018 Sep;8:14291.
- [31] Marlow R, Ferreira M, Cordeiro E, Trotter C, Januario L, Finn A, et al. Case control study of rotavirus vaccine effectiveness in Portugal during 6 years of private market use. Pediatr Infect Dis J. 2015 May;34(5):509-12.
- [32] Castilla J, Beristain X, Martinez-Artola V, Navascues A, Garcia Cenoz M, Alvarez N, et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. Vaccine. 2012;30:539-43.

	51
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	

[33] Mujuru HA, Burnett E, Nathoo KJ, Ticklay I, Gonah NA, Mukaratirwa A, et al. Monovalent rotavirus vaccine effectiveness against rotavirus hospitalizations among children in Zimbabwe. Clin Infect Dis. 2019 Oct 15;699(8):1339-44.

PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO .: V260-077/V6.0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024

12 ANNEX

Annex 1 List of stand-alone documents

No.	Document Reference No	Date	Title
1.	ER212-PV001, v3.0	1-May-2022	External Adverse Event and Product Quality Complaint Form
2.	<no></no>	<date></date>	<text></text>
Ν	<no></no>	<date></date>	<text></text>

	5
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
<u>REVOPS ID NO: NIS008322</u> EDIDEMIOLOCY NO (DE STUDIES ONLV); ED008011.022	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO. (PE STUDIES ONLY): EP008011.033	

Annex 2 Global Qualified Person for Pharmacovigilance (GQPPV), EU/UK QPPV



Dear Sir/Madam,

Re: Global, EU/UK QPPV Signature Page for PASS INN: Product: Protocol No: Epidemiology No: Protocol Date: MAH:

In line with the Guideline on Good Pharmacovigilance Practice (GVP), Module VIII - Post-Authorization Safety Studies (PASS) and according to MSD internal SOPs, this study has been reviewed and approved by the Global Qualified Person for the Pharmacovigilance (GQPPV), EU/UK QPPV.

Yours faithfully

Dr Peter De Veene Associate Vice President, Global Qualified Person for Pharmacovigilance (GQPPV) EU/UK QPPV

		54
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0	
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO.(PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024	

13 SIGNATURES

13.1 Sponsor's Representative

PRINTED NAME	PPD
TITLE	Study lead,
	Biostatistical and Research Decision Sciences (BARDS) Epidemiology,
	Merck Sharp & Dohme LLC.
SIGNATURE	
DATE SIGNED	

PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322	CORE DRC APPROVAL DATE: 7-JUNE-2024
EPIDEMIOLOGY NO (PE STUDIES ONLY) · EP008011.033	

13.2 Investigator

I agree to conduct this study in accordance with the design outlined in this protocol and to abide by all provisions of this protocol (including other project plans and documents referenced from this protocol); changes from the protocol are acceptable only with a mutually agreed upon protocol amendment. I agree to conduct the study in accordance with generally accepted standards of Good Pharmacoepidemiology Practice. I also agree to report all information or data in accordance with the protocol and, in particular, I agree to report any adverse events and product quality complaints as defined in the Safety and Product Quality Complaint Reporting and Related Procedures section. I understand that information that identifies me will be used and disclosed as described in the protocol and the Use and Disclosure of Personal Data notice provided to me, and that such information may be transferred to countries that do not have laws protecting such information. Since the information in this protocol is confidential, I understand that its disclosure to any third parties, other than those involved in approval, supervision, or conduct of the study is prohibited. I will ensure that the necessary precautions are taken to protect such information from loss, inadvertent disclosure, or access by third parties.

PRINTED NAME	Jie Wu
TITLE	Professor, MD Department of Gastroenterology, Beijing Children's Hospital
SIGNATURE	
DATE SIGNED	

	56
PRODUCT: V-260	PROTOCOL/AMENDMENT VERSION NO.: V260-077/V6.0
REVOPS ID NO: NIS008322 EPIDEMIOLOGY NO (PE STUDIES ONLY): EP008011.033	CORE DRC APPROVAL DATE: 7-JUNE-2024

13.3 Supplier

I agree to conduct this study in accordance with the design outlined in this protocol and to abide by all provisions of this protocol (including other manuals and documents referenced from this protocol); changes from the protocol are acceptable only with a mutually agreed upon protocol amendment. I agree to conduct the study in accordance with generally accepted standards of Good Pharmacoepidemiology Practice. I also agree to report all information or data in accordance with the protocol and, in particular, I agree to report any adverse events and product quality complaints as defined in the Safety and Product Quality Complaint Reporting and Related Procedures section. I understand that information that identifies me will be used and disclosed as described in the protocol and in order to perform any agreement between myself and the Sponsor, and that such information. Since the information in this protocol is confidential, I understand that its disclosure to any third parties, other than those involved in approval, supervision, or conduct of the study is prohibited. I will ensure that the necessary precautions are taken to protect such information from loss, inadvertent disclosure, or access by third parties.

PRINTED NAME	PPD
TITLE	Project Manager Hangzhou Tigermed Consulting Co.,Ltd
SIGNATURE	
DATE SIGNED	